CHEK2*1100delC homozygosity in the Netherlands—prevalence and risk of breast and lung cancer

[1]  R. Tsonaka,et al.  Combining Family and Twin Data in Association Studies to Estimate the Noninherited Maternal Antigens Effect , 2012, Genetic epidemiology.

[2]  Deborah Hughes,et al.  Gene-gene interactions in breast cancer susceptibility. , 2012, Human molecular genetics.

[3]  J. Foekens,et al.  Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes , 2012, Breast Cancer Research and Treatment.

[4]  A. W. van der Vaart,et al.  CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women , 2011, Journal of Medical Genetics.

[5]  X. Geng,et al.  Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. , 2011, European journal of cancer.

[6]  Paolo Boffetta,et al.  Genetics of lung-cancer susceptibility. , 2011, The Lancet. Oncology.

[7]  M. Look,et al.  Prevalence of the variant allele rs61764370 T>G in the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families , 2011, Breast Cancer Research and Treatment.

[8]  M. Southey,et al.  Detecting differential allelic expression using high-resolution melting curve analysis: application to the breast cancer susceptibility gene CHEK2 , 2011, BMC Medical Genomics.

[9]  Hongbing Shen,et al.  A variant in the CHEK2 promoter at a methylation site relieves transcriptional repression and confers reduced risk of lung cancer. , 2010, Carcinogenesis.

[10]  A. Hollestelle,et al.  Discovering moderate-risk breast cancer susceptibility genes. , 2010, Current opinion in genetics & development.

[11]  C. Begg,et al.  Evaluating Cancer Epidemiologic Risk Factors Using Multiple Primary Malignancies , 2010, Epidemiology.

[12]  J. Foekens,et al.  Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study , 2009, Breast Cancer Research.

[13]  M. Yin,et al.  Mice with the CHEK2*1100delC SNP are predisposed to cancer with a strong gender bias , 2009, Proceedings of the National Academy of Sciences.

[14]  P. Hainaut,et al.  The associations of sequence variants in DNA-repair and cell-cycle genes with cancer risk: genotype-phenotype correlations. , 2009, Biochemical Society transactions.

[15]  Paolo Vineis,et al.  Sequence variants at the TERT-CLPTM1L locus associate with many cancer types , 2009, Nature Genetics.

[16]  A. Ashworth,et al.  Family History, Genetic Testing, and Clinical Risk Prediction: Pooled Analysis of CHEK2*1100delC in 1,828 Bilateral Breast Cancers and 7,030 Controls , 2009, Cancer Epidemiology Biomarkers & Prevention.

[17]  D. Horsman,et al.  Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. , 2008, Cancer research.

[18]  A. Jakubowska,et al.  Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. , 2008, Carcinogenesis.

[19]  A. Børresen-Dale,et al.  Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study , 2008, British Journal of Cancer.

[20]  S. Bojesen,et al.  CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Olga Anczuków,et al.  Does the nonsense‐mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? , 2008, Human mutation.

[22]  J. Kładny,et al.  Common variants of DNA repair genes and malignant melanoma. , 2008, European journal of cancer.

[23]  Patricia L. Harris,et al.  Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts , 2007, International journal of cancer.

[24]  M. Garrett,et al.  CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin? , 2007, Nature Reviews Cancer.

[25]  P. Brennan,et al.  Inherited Predisposition of Lung Cancer: A Hierarchical Modeling Approach to DNA Repair and Cell Cycle Control Pathways , 2007, Cancer Epidemiology Biomarkers & Prevention.

[26]  J. Klijn,et al.  Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases , 2007, Breast Cancer Research.

[27]  R. Peto,et al.  Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study. , 2007, Human molecular genetics.

[28]  M. Yin,et al.  The breast cancer susceptibility allele CHEK2*1100delC promotes genomic instability in a knock-in mouse model. , 2007, Mutation research.

[29]  J. Klijn,et al.  Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study , 2007, Breast Cancer Research.

[30]  S. Seal,et al.  A Multicenter Study of Cancer Incidence in CHEK2 1100delC Mutation Carriers , 2006, Cancer Epidemiology Biomarkers & Prevention.

[31]  Søren Højsgaard,et al.  The R Package geepack for Generalized Estimating Equations , 2005 .

[32]  P. Devilee,et al.  Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype , 2005, The Journal of pathology.

[33]  A. Spurdle,et al.  Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals , 2005, British Journal of Cancer.

[34]  M. Schutte,et al.  Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant , 2004, Journal of Medical Genetics.

[35]  Douglas Easton,et al.  The Genetic Epidemiology of Breast Cancer Genes , 2004, Journal of Mammary Gland Biology and Neoplasia.

[36]  Nazneen Rahman,et al.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.

[37]  J. Klijn,et al.  Excess Risk for Contralateral Breast Cancer in CHEK2*1100delC Germline Mutation Carriers , 2004, Breast Cancer Research and Treatment.

[38]  J. Klijn,et al.  The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. , 2003, Cancer research.

[39]  J. Klijn,et al.  The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. , 2003, American journal of human genetics.

[40]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[41]  The Polish Breast Cancer Consortium.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .

[42]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[43]  J. Primrose,et al.  Optimisation of DNA and RNA extraction from archival formalin-fixed tissue. , 1999, Nucleic acids research.

[44]  A. Haworth,et al.  PCR amplification of 40-year-old paraffin-embedded tumor-tissues - comparison of 4 different DNA extraction and purification methods. , 1994, International journal of oncology.